KBP-8017 is a unique, multi-kinase inhibitor targeting Radiation-Induced Pulmonary Fibrosis, (including Delayed Effects of Acute Radiation Exposure (DEARE) fibrosis, radiation-induced lung injury in cancer patients) and Pulmonary Fibrosis due to other causes (including COVID-19 related Fibrosis and Idiopathic Pulmonary Fibrosis). KBP-8017 shows excellent activity in enzyme assays, as well as a PK profile suitable for once-daily dosing. KBP-8017 is in preclinical stage of development and may be eligible for orphan indications and the FDA Animal Rule regulatory pathway.